Pathogenic germline variants in breast cancer patients associated with different HER2 expression levels. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Fred Hutch Cancer Center researchers shared their latest findings at the annual meeting of the Society for Immunotherapy of Cancer (SITC), held in Houston from November 6-10. Fred Hutch faculty ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins ...

Investing.com -- TuHURA Biosciences Inc (NASDAQ:HURA) stock gained 2.8% premarket Monday after the company announced its research on the Delta Opioid Receptor (DOR) in cancer immunotherapy was ...

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources. Amino acids, once seen as passive nutrients ...